Ifnl3-KO Mouse
Common Name
Ifnl3-KO
제품 ID
S-KO-18327
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-338374-Ifnl3-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Ifnl3-KO Mouse (카탈로그 번호 S-KO-18327)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Ifnl3-KO
품종 계통계통 ID
KOCMP-338374-Ifnl3-B6J-VA
유전자명
제품 ID
S-KO-18327
유전자 별칭
Il28, IFL-1, Il28b, IL-28B, If1ia2, INF-alpha, INF-lambda
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 7
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000078364
NCBI 전사체 ID
NM_177396
타겟 영역
Exon 1~5
유효 영역 크기
~3.4 kb
유전자 연구 개요
Ifnl3, also known as IL28B, is a gene that encodes a protein belonging to the interferon lambda family. Interferons play crucial roles in the innate immune response, regulating the body's defense against viral infections and modulating immune cell functions. The pathways associated with Ifnl3 are related to antiviral responses and immune regulation, which are of great biological importance in maintaining the body's health [2,4,5,6]. Genetic models can be valuable in studying Ifnl3 to understand its precise functions and implications in disease.
In relation to diseases, Ifnl3 polymorphisms have been extensively studied. In COVID-19 patients, carriers of at least one variant allele of Ifnl3 rs8099917 were almost 36-fold more likely not to survive SARS-CoV-2 infection, indicating that this polymorphism significantly affects the outcome of COVID-19 [1]. For chronic hepatitis B (CHB) patients, two polymorphisms (rs12979860 and rs8099917) of Ifnl3 may play a crucial role in interferon-based treatment, especially in the HBeAg-positive group [2]. In systemic sclerosis, the Ifnl3 polymorphism is associated with pulmonary fibrosis, and serum IFN-λ3 levels are higher among subjects with pulmonary fibrosis [3]. Regarding hepatitis C virus (HCV) infections, Ifnl3 SNPs are the strongest baseline predictors of sustained virologic response to pegylated interferon and ribavirin therapy in HCV genotype 1, 2, or 3 infections [4,7]. An Ifnl3-adjuvanted HCV DNA vaccine can reduce regulatory T cell frequency and increase virus-specific T cell responses, showing potential in preventing HCV re-infection [8].
In conclusion, Ifnl3 is a key gene in the innate immune response, playing a significant role in various viral-related diseases such as COVID-19, hepatitis B, and hepatitis C, as well as in fibrotic conditions like pulmonary fibrosis in systemic sclerosis. Studies on Ifnl3, especially those involving its polymorphisms, help in understanding disease mechanisms and can potentially guide therapeutic decision-making for these diseases.
References：
1. Matic, Sanja, Milovanovic, Dragan, Mijailovic, Zeljko, Baskic, Dejan, Djordjevic, Natasa. . IFNL3/4 polymorphisms as a two-edged sword: An association with COVID-19 outcome. In Journal of medical virology, 95, e28506. doi:10.1002/jmv.28506. https://pubmed.ncbi.nlm.nih.gov/36655749/
2. Zhao, Zhongyi, Qin, Zhen, Zhou, Linlin, Wang, Baoning, Li, Mingyuan. 2019. The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. In Microbial pathogenesis, 134, 103598. doi:10.1016/j.micpath.2019.103598. https://pubmed.ncbi.nlm.nih.gov/31201901/
3. Metwally, Mayada, Thabet, Khaled, Bayoumi, Ali, George, Jacob, Eslam, Mohammed. 2019. IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. In Scientific reports, 9, 14834. doi:10.1038/s41598-019-50709-9. https://pubmed.ncbi.nlm.nih.gov/31619697/
4. Chinnaswamy, Sreedhar. 2014. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. In Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 34, 479-97. doi:10.1089/jir.2013.0113. https://pubmed.ncbi.nlm.nih.gov/24555572/
5. O'Connor, Kate S, Ahlenstiel, Golo, Suppiah, Vijayaprakash, George, Jacob, Booth, David R. 2013. IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. In Innate immunity, 20, 598-605. doi:10.1177/1753425913503385. https://pubmed.ncbi.nlm.nih.gov/24045339/
6. O'Connor, Kate S, George, Jacob, Booth, David, Ahlenstiel, Golo. . Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. In World journal of gastroenterology, 20, 17830-8. doi:10.3748/wjg.v20.i47.17830. https://pubmed.ncbi.nlm.nih.gov/25548481/
7. Eslam, Mohammed, Leung, Reynold, Romero-Gomez, Manuel, George, Jacob, Ahlenstiel, Golo. 2014. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. In Journal of hepatology, 61, 235-41. doi:10.1016/j.jhep.2014.03.039. https://pubmed.ncbi.nlm.nih.gov/24768758/
8. Han, Ji Won, Sung, Pil Soo, Hong, Seon-Hui, Ahn, Sang Hoon, Shin, Eui-Cheol. 2020. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. In Journal of hepatology, 73, 72-83. doi:10.1016/j.jhep.2020.02.009. https://pubmed.ncbi.nlm.nih.gov/32088322/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.